161 related articles for article (PubMed ID: 34761631)
1. The effect of adjuvant chemotherapy on the survival of patients with high-risk soft tissue sarcomas: Single center experience.
Eraslan E; Ilhan Gulesen A; Yildiz F; Tufan G; Yalcintas Arslan U; Alkis N
J BUON; 2021; 26(5):2169-2175. PubMed ID: 34761631
[TBL] [Abstract][Full Text] [Related]
2. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
[TBL] [Abstract][Full Text] [Related]
3. Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304.
Tanaka K; Mizusawa J; Naka N; Kawai A; Katagiri H; Hiruma T; Matsumoto Y; Tsuchiya H; Nakayama R; Hatano H; Emori M; Watanuki M; Yoshida Y; Okamoto T; Abe S; Asanuma K; Yokoyama R; Hiraga H; Yonemoto T; Morii T; Ae K; Nagano A; Yoshikawa H; Fukuda H; Ozaki T; Iwamoto Y
BMC Cancer; 2019 Sep; 19(1):890. PubMed ID: 31492159
[TBL] [Abstract][Full Text] [Related]
4. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
Woll PJ; Reichardt P; Le Cesne A; Bonvalot S; Azzarelli A; Hoekstra HJ; Leahy M; Van Coevorden F; Verweij J; Hogendoorn PC; Ouali M; Marreaud S; Bramwell VH; Hohenberger P;
Lancet Oncol; 2012 Oct; 13(10):1045-54. PubMed ID: 22954508
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Bramwell V; Rouesse J; Steward W; Santoro A; Schraffordt-Koops H; Buesa J; Ruka W; Priario J; Wagener T; Burgers M
J Clin Oncol; 1994 Jun; 12(6):1137-49. PubMed ID: 8201375
[TBL] [Abstract][Full Text] [Related]
8. A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma.
Schmitt T; Lehner B; Kasper B; Bischof M; Roeder F; Dietrich S; Dimitrakopoulou-Strauss A; Strauss LG; Mechtersheimer G; Wuchter P; Ho AD; Egerer G
BMC Cancer; 2011 Dec; 11():510. PubMed ID: 22152120
[TBL] [Abstract][Full Text] [Related]
9. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
Gronchi A; Frustaci S; Mercuri M; Martin J; Lopez-Pousa A; Verderio P; Mariani L; Valagussa P; Miceli R; Stacchiotti S; Dei Tos AP; De Paoli A; Longhi A; Poveda A; Quagliuolo V; Comandone A; Casali PG; Picci P
J Clin Oncol; 2012 Mar; 30(8):850-6. PubMed ID: 22312103
[TBL] [Abstract][Full Text] [Related]
10. The role of adjuvant chemotherapy in children and adolescents with surgically resected, high-risk adult-type soft tissue sarcomas.
Ferrari A; Brecht IB; Koscielniak E; Casanova M; Scagnellato A; Bisogno G; Alaggio R; Cecchetto G; Catania S; Meazza C; Int-Veen C; Kirsch S; Dantonello T; Carli M; Treuner J
Pediatr Blood Cancer; 2005 Aug; 45(2):128-34. PubMed ID: 15852434
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Worden FP; Taylor JM; Biermann JS; Sondak VK; Leu KM; Chugh R; McGinn CJ; Zalupski MM; Baker LH
J Clin Oncol; 2005 Jan; 23(1):105-12. PubMed ID: 15625365
[TBL] [Abstract][Full Text] [Related]
12. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
Pasquali S; Pizzamiglio S; Touati N; Litiere S; Marreaud S; Kasper B; Gelderblom H; Stacchiotti S; Judson I; Dei Tos AP; Verderio P; Casali PG; Woll PJ; Gronchi A;
Eur J Cancer; 2019 Mar; 109():51-60. PubMed ID: 30690293
[TBL] [Abstract][Full Text] [Related]
13. Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma: A Report of Twenty-Eight Patients.
Wang B; Yu X; Xu S; Xu M
Medicine (Baltimore); 2016 Jan; 95(4):e2611. PubMed ID: 26825914
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.
Frustaci S; Gherlinzoni F; De Paoli A; Bonetti M; Azzarelli A; Comandone A; Olmi P; Buonadonna A; Pignatti G; Barbieri E; Apice G; Zmerly H; Serraino D; Picci P
J Clin Oncol; 2001 Mar; 19(5):1238-47. PubMed ID: 11230464
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide.
Weh HJ; Zügel M; Wingberg D; Schwarz R; Zornig C; Dietel M; Hossfeld DK
Onkologie; 1990 Dec; 13(6):448-52. PubMed ID: 2128712
[TBL] [Abstract][Full Text] [Related]
16. Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma.
Noujaim J; Constantinidou A; Messiou C; Thway K; Miah A; Benson C; Judson I; Jones RL
Am J Clin Oncol; 2018 Feb; 41(2):147-151. PubMed ID: 26523439
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy influences the pseudocapsule composition in soft tissue sarcomas.
O'Donnell PW; Manivel JC; Cheng EY; Clohisy DR
Clin Orthop Relat Res; 2014 Mar; 472(3):849-55. PubMed ID: 23640206
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy for patients with soft tissue sarcoma.
Ozaki T; Sugihara S; Hamada M; Nakagawa Y; Inoue H
Hiroshima J Med Sci; 1993 Sep; 42(3):109-15. PubMed ID: 8253605
[TBL] [Abstract][Full Text] [Related]
19. Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis.
Hua Q; Xu G; Zhao L; Zhang T
J Chemother; 2021 Sep; 33(5):319-327. PubMed ID: 33501892
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Edmonson JH; Petersen IA; Shives TC; Mahoney MR; Rock MG; Haddock MG; Sim FH; Maples WJ; O'Connor MI; Gunderson LL; Foo ML; Pritchard DJ; Buckner JC; Stafford SL
Cancer; 2002 Feb; 94(3):786-92. PubMed ID: 11857314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
